Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Guardant Health, Inc. - Common Stock (NQ:GH)

97.97 -1.97 (-1.97%)

Streaming Delayed Price Updated: 10:53 AM EDT, May 13, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	334,620
Open	99.14
Bid (Size)	97.79 (100)
Ask (Size)	98.00 (100)
Prev. Close	99.94
Today's Range	95.60 - 99.14
52wk Range	36.36 - 120.74
Shares Outstanding	101,298,669
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Guardant Health (GH) Q1 2026 Earnings Transcript ↗

May 08, 2026

Guardant Health (GH) Q1 2026 Earnings Transcript

Via The Motley Fool

GH Q1 Deep Dive: Shield Volume Acceleration and Oncology Portfolio Expansion Fuel Growth

May 08, 2026

Diagnostics company Guardant Health (NASDAQ:GH) announced better-than-expected revenue in Q1 CY2026, with sales up 48.3% year on year to $301.7 million. The ...

Via StockStory

Performance

YTD	-3.7%	-3.7%
1 Month	+19.2%	+19.2%
3 Month	-6.7%	-6.7%
6 Month	+0.3%	+0.3%
1 Year	+135.2%	+135.2%

More News

Guardant Health (NASDAQ:GH) Delivers Impressive Q1 CY2026, Stock Soars

May 07, 2026

Via StockStory

Guardant Health (NASDAQ:GH) Smashes Q1 Estimates, Raises Full-Year Guidance on Soaring Screening Revenue ↗

May 07, 2026

Via Chartmill

Guardant Health Reports First Quarter 2026 Financial Results and Increases 2026 Revenue Guidance

May 07, 2026

From Guardant Health, Inc.

Via Business Wire

Guardant Health Earnings: What To Look For From GH

May 05, 2026

Via StockStory

Guardant Health Receives FDA Approval for Guardant360® CDx as a Companion Diagnostic for Arvinas and Pfizer’s VEPPANU (vepdegestrant) for Patients with ER+/HER2- Advanced Breast Cancer with ESR1 Mutations

May 04, 2026

From Guardant Health, Inc.

Via Business Wire

Guardant Health Announces Multi-Year Strategic Collaboration with Nuvalent to Develop Companion Diagnostics and Support Potential Commercialization of Targeted Cancer Therapies Using the Guardant Infinity™ Platform

April 30, 2026

From Guardant Health, Inc.

Via Business Wire

Guardant Health to Participate in Upcoming Investor Conferences

April 29, 2026

From Guardant Health, Inc.

Via Business Wire

Guardant Health to Report First Quarter 2026 Financial Results on May 7, 2026

April 16, 2026

From Guardant Health, Inc.

Via Business Wire

Guardant Health, Organon, Fortrea, QuidelOrtho, and Charles River Laboratories Stocks Trade Down, What You Need To Know

April 06, 2026

Via StockStory

1 Healthcare Stock with Exciting Potential and 2 Facing Headwinds

April 02, 2026

Via StockStory

Why Is Guardant Health (GH) Stock Soaring Today

March 31, 2026

Via StockStory

Guardant Health’s InfinityAI Real-World Evidence Supports Approval of ENHERTU® for Previously Treated Patients with HER2-Positive Metastatic Solid Tumors in Japan

March 30, 2026

From Guardant Health, Inc.

Via Business Wire

Why Guardant Health (GH) Stock Is Falling Today

March 27, 2026

Via StockStory

3 Growth Stocks We Think Twice About

March 26, 2026

Via StockStory

Abbott Laboratories Finalizes $21 Billion Acquisition of Exact Sciences, Redefining the Future of Cancer Diagnostics

March 23, 2026

Via MarketMinute

3 Reasons to Avoid GH and 1 Stock to Buy Instead

March 19, 2026

Via StockStory

Guardant Health to Present 28 Abstracts Highlighting Advances in Tumor Typing, Therapy Selection and Expanded Utility of Multiomic Tissue and Liquid Biopsy Testing at AACR 2026

March 18, 2026

From Guardant Health, Inc.

Via Business Wire

Guardant Health Launches Shield Multi-Cancer Detection (MCD) Test in Multiple Markets in Asia with Manulife Partnership

March 16, 2026

From Guardant Health, Inc.

Via Business Wire

This Fund Has a $200 Million Bet on a Biotech Stock Up 30% in Days After Phase 3 Breakthrough ↗

March 13, 2026

Via The Motley Fool

Battery Storage Stock Up 50% in a Year Draws New $110M Investment. Here's What You Should Know ↗

March 13, 2026

Via The Motley Fool

Biotech Stock Up 685% Draws $80.5 Million Investment Amid Dual FDA Filings ↗

March 13, 2026

Via The Motley Fool

New Guardant Health/Harris Poll Survey Shows 92% of All Eligible Americans Believe Colorectal Cancer Blood Tests Should be Accessible and Covered Similar to Medicare

March 13, 2026

From Guardant Health, Inc.

Via Business Wire

Guardant Health’s Shield Blood-based Screening Test for Colorectal Cancer Now Accessible Through National Test Ordering and Collection Network of Quest Diagnostics

March 10, 2026

From Guardant Health, Inc.

Via Business Wire

Frequently Asked Questions

Is Guardant Health, Inc. - Common Stock publicly traded?

Yes, Guardant Health, Inc. - Common Stock is publicly traded.

What exchange does Guardant Health, Inc. - Common Stock trade on?

Guardant Health, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Guardant Health, Inc. - Common Stock?

The ticker symbol for Guardant Health, Inc. - Common Stock is GH on the Nasdaq Stock Market

What is the current price of Guardant Health, Inc. - Common Stock?

The current price of Guardant Health, Inc. - Common Stock is 97.97

When was Guardant Health, Inc. - Common Stock last traded?

The last trade of Guardant Health, Inc. - Common Stock was at 05/13/26 10:53 AM ET

What is the market capitalization of Guardant Health, Inc. - Common Stock?

The market capitalization of Guardant Health, Inc. - Common Stock is 9.92B

How many shares of Guardant Health, Inc. - Common Stock are outstanding?

Guardant Health, Inc. - Common Stock has 10B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.